Non-small-cell lung cancer: how to manage RET-positive disease

• المؤلفون الرئيسيون: Elisa Andrini (مؤلف), Mirta Mosca (مؤلف), Linda Galvani (مؤلف), Francesca Sperandi (مؤلف), Biagio Ricciuti (مؤلف), Giulio Metro (مؤلف), Giuseppe Lamberti (مؤلف)
• التنسيق: كتاب
• منشور في: BioExcel Publishing Ltd, 2022-07-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Targeted therapy has dramatically changed the history and outcomes of oncogene-addicted non-small-cell lung cancer (NSCLC). RET rearrangements are typically observed in about 1-2% of NSCLC, resulting in constitutive activation of downstream signalling pathways commonly involved in cell growth and su...